Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome

• Published in: Pediatric Blood & Cancer Vol. 51; no. 3; pp. 418 - 420
• Main Authors: Smith, Angela R., Hennessy, Jane M., Kurth, Margaret A. Heisel, Nelson, Stephen C.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.09.2008
• Subjects: Angiogenesis Inhibitors - adverse effects; Angiogenesis Inhibitors - therapeutic use; Angiomatosis - complications; Angiomatosis - drug therapy; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized; avastin; Bevacizumab; Bone Diseases - chemically induced; bony toxicity; CAT syndrome; Humans; Infant; Vascular Endothelial Growth Factor A - antagonists & inhibitors

Cutaneovisceral angiomatosis with thrombocytopenia (CAT) syndrome is a rare vascular disorder of the skin and gastrointestinal tract for which there is no standard treatment. We present a case in which a child with CAT syndrome was treated with bevacizumab, a vascular endothelial growth factor inhib...